Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell CarcinomaMartin H. Voss, Darren R. Feldman, Joshua Chaim et al.|Journal of Clinical Oncology|2016Cited by 85
A phase II trial of everolimus (E) and bevacizumab (B) in advanced non-clear cell renal cell cancer (ncRCC) to show efficacy in patients (pts) with papillary features.Martin H. Voss, Darren R. Feldman, Ying‐Bei Chen et al.|Journal of Clinical Oncology|2015Cited by 1